董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Christopher Bunka | 男 | Chairman, Chief Executive Officer and Director | 61 | 29.12万美元 | 未持股 | 2023-11-20 |
| John Docherty | 男 | President and Director | 52 | 29.05万美元 | 未持股 | 2023-11-20 |
| Nicholas Baxter | 男 | Director | 69 | 5.54万美元 | 未持股 | 2023-11-20 |
| Ted McKechnie | 男 | Director | 75 | 未披露 | 未持股 | 2023-11-20 |
| Al Reese Jr. | 男 | Director | 73 | 未披露 | 未持股 | 2023-11-20 |
| Catherine Turkel | 女 | Director | 63 | 未披露 | 未持股 | 2023-11-20 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Christopher Bunka | 男 | Chairman, Chief Executive Officer and Director | 61 | 29.12万美元 | 未持股 | 2023-11-20 |
| John Docherty | 男 | President and Director | 52 | 29.05万美元 | 未持股 | 2023-11-20 |
董事简历
中英对照 | 中文 | 英文- Christopher Bunka
-
Christopher Bunka自2006年以来一直担任董事会主席兼首席执行官，主要负责公司从较早的业务活动转向生物科学。Bunka先生是一位连续企业家，自1980年末以来一直在几家私营和上市公司工作。他作为印刷和广播电台的兼职商业评论员以及作家而闻名十多年。他在资本市场，公司治理，项目收购和公司融资方面拥有丰富的经验。他是该公司一些正在申请专利的发明家。自1988年以来，Bunka先生一直担任CAB Financial Services Ltd.的首席执行官，这是一家位于加拿大基洛纳的私人控股公司。他是一位风险投资家和企业顾问。
Christopher Bunka,– Chairman, Chief Executive Officer and Director Mr. Bunka has been Chairman of the Board and CEO since 2006 and was primarily responsible for the corporate pivot from older business activities to bioscience. Mr. Bunka is a serial entrepreneur and has been involved in several private and public companies since the late 1980's. He was well known for more than a decade as a part-time business commentator in print and radio, as well as an author. He has extensive experience in the capital markets, corporate governance, project acquisition and corporate finance. He is a named inventor on several of Lexaria's pending patents. Since 1988, Mr. Bunka has been the CEO of CAB Financial Services Ltd., a private holding company located in Kelowna, BC, Canada. He is a venture capitalist and corporate consultant. - Christopher Bunka自2006年以来一直担任董事会主席兼首席执行官，主要负责公司从较早的业务活动转向生物科学。Bunka先生是一位连续企业家，自1980年末以来一直在几家私营和上市公司工作。他作为印刷和广播电台的兼职商业评论员以及作家而闻名十多年。他在资本市场，公司治理，项目收购和公司融资方面拥有丰富的经验。他是该公司一些正在申请专利的发明家。自1988年以来，Bunka先生一直担任CAB Financial Services Ltd.的首席执行官，这是一家位于加拿大基洛纳的私人控股公司。他是一位风险投资家和企业顾问。
- Christopher Bunka,– Chairman, Chief Executive Officer and Director Mr. Bunka has been Chairman of the Board and CEO since 2006 and was primarily responsible for the corporate pivot from older business activities to bioscience. Mr. Bunka is a serial entrepreneur and has been involved in several private and public companies since the late 1980's. He was well known for more than a decade as a part-time business commentator in print and radio, as well as an author. He has extensive experience in the capital markets, corporate governance, project acquisition and corporate finance. He is a named inventor on several of Lexaria's pending patents. Since 1988, Mr. Bunka has been the CEO of CAB Financial Services Ltd., a private holding company located in Kelowna, BC, Canada. He is a venture capitalist and corporate consultant.
- John Docherty
-
John Docherty被任命为公司总裁，于2015年4月15日生效。在加入公司之前，Docherty先生是HELIX BIOPHARMACORP.的前总裁兼首席运营官。TSX:HBP，在那里他领导公司的植物和重组衍生的治疗性蛋白质候选产品的药物开发计划。Docherty先生是一位高级运营和管理执行官，在制药和生物制药领域拥有20多年的经验。他曾与大型跨国公司以及新兴的私营和上市初创企业合作。在Helix，Docherty先生还在投资者/利益相关者关系，资本筹集，资本市场发展，战略合作伙伴关系，监管机构互动和媒体关系领域发挥了重要作用，他还担任其董事会管理成员。在此之前，Docherty先生是Pharmaderm Laboratories Ltd.的总裁兼董事会成员，Pharmaderm Laboratories Ltd.是一家加拿大药物输送公司，开发了独特的微胶囊制剂技术，可用于一系列活性化合物。Docherty先生还曾在Astra Pharma Inc.，Nu-Pharm Inc.和Price Water House Coopers’；前全球制药行业咨询业务等公司任职。他是已发布专利和未决专利申请的指定发明人，并拥有理学硕士学位。药理学学士学位。多伦多大学毒理学博士学位。自2016年4月29日起担任公司董事。
John Docherty,was appointed President of Lexaria effective April 15, 2015. Prior to Lexaria Mr. Docherty was former President and Chief Operating Officer of Helix BioPharma Corp. (TSX: HBP), where he led the company's pharmaceutical development programs for its plant and recombinantly derived therapeutic protein product candidates.Mr. Docherty is a senior operations and management executive with over 20 years' experience in the pharmaceutical and biopharmaceutical sectors. He has worked with large multinational companies and emerging, private and publicly held start-ups. At Helix, Mr. Docherty was instrumental in the areas of investor/stakeholder relations, capital raising, capital markets development, strategic partnering, regulatory authority interactions and media relations. He also served as a management member of its board of directors. Previously, Mr. Docherty was President and a board member of PharmaDerm Laboratories Ltd., a Canadian drug delivery company that developed unique microencapsulation formulation technologies for Lexaria Bioscience Corp. e with a range of active compounds.Mr. Docherty also held positions with companies such as Astra Pharma Inc., Nu-Pharm Inc. and PricewaterhouseCoopers' former global pharmaceutical industry consulting practice. He is a named inventor on issued and pending patents and he has a M.Sc. in pharmacology and a B.Sc. in Toxicology from the University of Toronto. He has served as a director of Lexaria since April 29, 2016. - John Docherty被任命为公司总裁，于2015年4月15日生效。在加入公司之前，Docherty先生是HELIX BIOPHARMACORP.的前总裁兼首席运营官。TSX:HBP，在那里他领导公司的植物和重组衍生的治疗性蛋白质候选产品的药物开发计划。Docherty先生是一位高级运营和管理执行官，在制药和生物制药领域拥有20多年的经验。他曾与大型跨国公司以及新兴的私营和上市初创企业合作。在Helix，Docherty先生还在投资者/利益相关者关系，资本筹集，资本市场发展，战略合作伙伴关系，监管机构互动和媒体关系领域发挥了重要作用，他还担任其董事会管理成员。在此之前，Docherty先生是Pharmaderm Laboratories Ltd.的总裁兼董事会成员，Pharmaderm Laboratories Ltd.是一家加拿大药物输送公司，开发了独特的微胶囊制剂技术，可用于一系列活性化合物。Docherty先生还曾在Astra Pharma Inc.，Nu-Pharm Inc.和Price Water House Coopers’；前全球制药行业咨询业务等公司任职。他是已发布专利和未决专利申请的指定发明人，并拥有理学硕士学位。药理学学士学位。多伦多大学毒理学博士学位。自2016年4月29日起担任公司董事。
- John Docherty,was appointed President of Lexaria effective April 15, 2015. Prior to Lexaria Mr. Docherty was former President and Chief Operating Officer of Helix BioPharma Corp. (TSX: HBP), where he led the company's pharmaceutical development programs for its plant and recombinantly derived therapeutic protein product candidates.Mr. Docherty is a senior operations and management executive with over 20 years' experience in the pharmaceutical and biopharmaceutical sectors. He has worked with large multinational companies and emerging, private and publicly held start-ups. At Helix, Mr. Docherty was instrumental in the areas of investor/stakeholder relations, capital raising, capital markets development, strategic partnering, regulatory authority interactions and media relations. He also served as a management member of its board of directors. Previously, Mr. Docherty was President and a board member of PharmaDerm Laboratories Ltd., a Canadian drug delivery company that developed unique microencapsulation formulation technologies for Lexaria Bioscience Corp. e with a range of active compounds.Mr. Docherty also held positions with companies such as Astra Pharma Inc., Nu-Pharm Inc. and PricewaterhouseCoopers' former global pharmaceutical industry consulting practice. He is a named inventor on issued and pending patents and he has a M.Sc. in pharmacology and a B.Sc. in Toxicology from the University of Toronto. He has served as a director of Lexaria since April 29, 2016.
- Nicholas Baxter
-
Nicholas Baxter于2009年被任命为Lexaria Corp.董事会成员。巴克斯特先生于1975年获得利物浦大学理学学士学位，并在世界许多地区从事石油和天然气项目。自20世纪80年代以来，他一直在英国和加拿大的上市公司工作。巴克斯特先生作为董事会成员带来了丰富的现实世界经验。巴克斯特先生是公司审计与财务委员会，薪酬委员会以及公司治理与提名委员会的独立成员。
Nicholas Baxter was appointed as a member of the board of directors of Lexaria Corp. in 2009. Mr. Baxter received a Bachelor of Science (Honours) from the University of Liverpool in 1975 and has worked on oil & gas projects in many areas of the world. Since the 1980's, he has worked with companies in the public markets both in the U.K. and in Canada. - Nicholas Baxter于2009年被任命为Lexaria Corp.董事会成员。巴克斯特先生于1975年获得利物浦大学理学学士学位，并在世界许多地区从事石油和天然气项目。自20世纪80年代以来，他一直在英国和加拿大的上市公司工作。巴克斯特先生作为董事会成员带来了丰富的现实世界经验。巴克斯特先生是公司审计与财务委员会，薪酬委员会以及公司治理与提名委员会的独立成员。
- Nicholas Baxter was appointed as a member of the board of directors of Lexaria Corp. in 2009. Mr. Baxter received a Bachelor of Science (Honours) from the University of Liverpool in 1975 and has worked on oil & gas projects in many areas of the world. Since the 1980's, he has worked with companies in the public markets both in the U.K. and in Canada.
- Ted McKechnie
-
Ted McKechnie是加拿大食品行业公认的思想领袖。过去，McKechnie先生是枫叶食品公司的总裁，Humpty Dumpty公司的所有者和高级管理人员，以及百事可乐公司的高级领导人。在从事食品制造的高管和营销人员的杰出职业生涯之后，他现在专注于将加拿大食品行业推向未来。除了担任FoodStarter&8217；S董事会主席外，McKechnie先生还担任戴维斯集团和威廉戴维斯咨询公司的董事长/首席执行官。McKechnie先生还是食品制造先进技术委员会主席，也是圣杰罗姆大学的董事会成员。智囊团、政府和行业领袖经常呼吁麦凯奇就如何发展食品行业、为加拿大经济增加更多价值发表见解。McKechnie先生是公司审计与财务委员会及其薪酬委员会的独立成员。
Ted McKechnie,– Director Mr. McKechnie is a well-recognized thought leader in the Canadian food industry. In the past, Mr. McKechnie was president of Maple Leaf Foods, an owner and senior executive at Humpty Dumpty Snack Foods and a senior leader at Pepsi Co. After a distinguished career as an executive and marketer specializing in food manufacturing, he now focuses on moving the Canadian food sector into the future. Aside from being the chairman of Food Starter's board, Mr. McKechnie is also the Chairman/CEO of The Davies Group and William Davies Consulting Inc. He is also a chairman of the board for Advanced Technology For Food Manufacturing, and serves on the Board Of Governors for St Jerome's University. Mr. McKechnie is often called upon by think tanks, government and industry leaders to offer insights on how to grow the food sector and add value to the Canadian economy. - Ted McKechnie是加拿大食品行业公认的思想领袖。过去，McKechnie先生是枫叶食品公司的总裁，Humpty Dumpty公司的所有者和高级管理人员，以及百事可乐公司的高级领导人。在从事食品制造的高管和营销人员的杰出职业生涯之后，他现在专注于将加拿大食品行业推向未来。除了担任FoodStarter&8217；S董事会主席外，McKechnie先生还担任戴维斯集团和威廉戴维斯咨询公司的董事长/首席执行官。McKechnie先生还是食品制造先进技术委员会主席，也是圣杰罗姆大学的董事会成员。智囊团、政府和行业领袖经常呼吁麦凯奇就如何发展食品行业、为加拿大经济增加更多价值发表见解。McKechnie先生是公司审计与财务委员会及其薪酬委员会的独立成员。
- Ted McKechnie,– Director Mr. McKechnie is a well-recognized thought leader in the Canadian food industry. In the past, Mr. McKechnie was president of Maple Leaf Foods, an owner and senior executive at Humpty Dumpty Snack Foods and a senior leader at Pepsi Co. After a distinguished career as an executive and marketer specializing in food manufacturing, he now focuses on moving the Canadian food sector into the future. Aside from being the chairman of Food Starter's board, Mr. McKechnie is also the Chairman/CEO of The Davies Group and William Davies Consulting Inc. He is also a chairman of the board for Advanced Technology For Food Manufacturing, and serves on the Board Of Governors for St Jerome's University. Mr. McKechnie is often called upon by think tanks, government and industry leaders to offer insights on how to grow the food sector and add value to the Canadian economy.
- Al Reese Jr.
-
小艾尔·里斯（Al Reese Jr.）已同意在本次发行结束后加入董事会。Reese先生在公共和私人企业拥有40多年的经验，并曾在能源公司和商业银行担任董事会职务。他曾担任数十亿公共能源公司的首席财务官，并指导了50多项收购和融资，规模从几十万美元到数十亿美元不等。Reese先生从1999年到2014年担任ATP Oil and Gas的首席财务官，在此期间，他指导ATP进行了总计超过100亿美元的股权，债务和夹层交易。Reese先生于1971年获得德克萨斯农工大学工商管理金融学学士学位，并于1977年获得休斯敦大学工商管理硕士学位，是一名注册会计师。
Al Reese Jr.,has over 50 years' experience in public and private businesses including as CFO of a formerly Nasdaq-listed energy company where he arranged finance transactions totalling over $10 billion dollars during his 20-year tenure. Mr. Reese was a Director and Chairman of the Audit Committee of a community bank in Texas for ten years until such time as it was acquired by a larger banking group in 2018. He currently serves as an Independent Director and Chairman of the Audit Committee for a privately held insurance company headquartered in The Woodlands, Texas. He has directed over 50 acquisitions and financings from as small as a few hundred thousand dollars to multibillion dollar transactions in both the domestic and international arenas. Mr. Reese is also President and Chairman of a family charitable 501(c)-3 foundation and Interim Chairman of a charitable 501(c)-3 entity that focus on Bible literacy.Mr. Reese is a Certified Public Accountant (1974) and received his Bachelor of Business Administration degree from Texas A&M University in 1971, and his MBA from University of Houston in 1977. - 小艾尔·里斯（Al Reese Jr.）已同意在本次发行结束后加入董事会。Reese先生在公共和私人企业拥有40多年的经验，并曾在能源公司和商业银行担任董事会职务。他曾担任数十亿公共能源公司的首席财务官，并指导了50多项收购和融资，规模从几十万美元到数十亿美元不等。Reese先生从1999年到2014年担任ATP Oil and Gas的首席财务官，在此期间，他指导ATP进行了总计超过100亿美元的股权，债务和夹层交易。Reese先生于1971年获得德克萨斯农工大学工商管理金融学学士学位，并于1977年获得休斯敦大学工商管理硕士学位，是一名注册会计师。
- Al Reese Jr.,has over 50 years' experience in public and private businesses including as CFO of a formerly Nasdaq-listed energy company where he arranged finance transactions totalling over $10 billion dollars during his 20-year tenure. Mr. Reese was a Director and Chairman of the Audit Committee of a community bank in Texas for ten years until such time as it was acquired by a larger banking group in 2018. He currently serves as an Independent Director and Chairman of the Audit Committee for a privately held insurance company headquartered in The Woodlands, Texas. He has directed over 50 acquisitions and financings from as small as a few hundred thousand dollars to multibillion dollar transactions in both the domestic and international arenas. Mr. Reese is also President and Chairman of a family charitable 501(c)-3 foundation and Interim Chairman of a charitable 501(c)-3 entity that focus on Bible literacy.Mr. Reese is a Certified Public Accountant (1974) and received his Bachelor of Business Administration degree from Texas A&M University in 1971, and his MBA from University of Houston in 1977.
- Catherine Turkel
-
Catherine Turkel在初创和中型制药/生物技术公司有20多年的高管经验。她是Nezee Therapeutics的Founder兼首席执行官，并曾担任Novus Therapeutics（更名为Eledon制药– Nasdaq：ELDN）的总裁兼研发主管。她目前在Object Pharma（私营）和Prostate Cancer Research（非营利组织；转化科学咨询委员会成员）担任独立董事，并担任查普曼大学药学院院长顾问。Turkel博士制定了注册和商业战略计划，并领导了与神经科学、疼痛、心血管、精神病学、罕见病、眼科、美学、泌尿外科和五官科治疗领域相关的药物和生物治疗从第一阶段到第四阶段的全球开发计划。特克尔博士设计并领导了艾尔建（现艾伯维-纽约证券交易所代码：ABBV）率先开发的BOTOX慢性偏头痛登记项目，该项目创造了超过10亿美元的收入。
Catherine Turkel,has more than 20 years' experience as an executive in start-up and mid-size pharma/biotech companies. She was Founder and CEO of Nezee Therapeutics, and served as President and R&D head at Novus Therapeutics (renamed Eledon Pharmaceuticals – Nasdaq: ELDN). She currently acts as an independent Board Director at Object Pharma (private) and Prostate Cancer Research (nonprofit; member of the Translational Scientific Advisory Committee) and is a Dean Advisor at Chapman University School of Pharmacy.Dr. Turkel has formulated registration & commercial strategic plans and has led global development programs for pharmaceutical and biologic treatments from phase 1 through phase 4 related to Neurosciences, Pain, Cardiovascular, Psychiatry, Rare Diseases, Ophthalmology, Aesthetics, Urology and Otology therapeutic areas. Dr. Turkel designed and led Allergan's (now AbbVie -NYSE: ABBV) pioneering BOTOX Chronic Migraine registration program, generating revenue of more than a billion dollars. - Catherine Turkel在初创和中型制药/生物技术公司有20多年的高管经验。她是Nezee Therapeutics的Founder兼首席执行官，并曾担任Novus Therapeutics（更名为Eledon制药– Nasdaq：ELDN）的总裁兼研发主管。她目前在Object Pharma（私营）和Prostate Cancer Research（非营利组织；转化科学咨询委员会成员）担任独立董事，并担任查普曼大学药学院院长顾问。Turkel博士制定了注册和商业战略计划，并领导了与神经科学、疼痛、心血管、精神病学、罕见病、眼科、美学、泌尿外科和五官科治疗领域相关的药物和生物治疗从第一阶段到第四阶段的全球开发计划。特克尔博士设计并领导了艾尔建（现艾伯维-纽约证券交易所代码：ABBV）率先开发的BOTOX慢性偏头痛登记项目，该项目创造了超过10亿美元的收入。
- Catherine Turkel,has more than 20 years' experience as an executive in start-up and mid-size pharma/biotech companies. She was Founder and CEO of Nezee Therapeutics, and served as President and R&D head at Novus Therapeutics (renamed Eledon Pharmaceuticals – Nasdaq: ELDN). She currently acts as an independent Board Director at Object Pharma (private) and Prostate Cancer Research (nonprofit; member of the Translational Scientific Advisory Committee) and is a Dean Advisor at Chapman University School of Pharmacy.Dr. Turkel has formulated registration & commercial strategic plans and has led global development programs for pharmaceutical and biologic treatments from phase 1 through phase 4 related to Neurosciences, Pain, Cardiovascular, Psychiatry, Rare Diseases, Ophthalmology, Aesthetics, Urology and Otology therapeutic areas. Dr. Turkel designed and led Allergan's (now AbbVie -NYSE: ABBV) pioneering BOTOX Chronic Migraine registration program, generating revenue of more than a billion dollars.
高管简历
中英对照 | 中文 | 英文- Christopher Bunka
Christopher Bunka自2006年以来一直担任董事会主席兼首席执行官，主要负责公司从较早的业务活动转向生物科学。Bunka先生是一位连续企业家，自1980年末以来一直在几家私营和上市公司工作。他作为印刷和广播电台的兼职商业评论员以及作家而闻名十多年。他在资本市场，公司治理，项目收购和公司融资方面拥有丰富的经验。他是该公司一些正在申请专利的发明家。自1988年以来，Bunka先生一直担任CAB Financial Services Ltd.的首席执行官，这是一家位于加拿大基洛纳的私人控股公司。他是一位风险投资家和企业顾问。
Christopher Bunka,– Chairman, Chief Executive Officer and Director Mr. Bunka has been Chairman of the Board and CEO since 2006 and was primarily responsible for the corporate pivot from older business activities to bioscience. Mr. Bunka is a serial entrepreneur and has been involved in several private and public companies since the late 1980's. He was well known for more than a decade as a part-time business commentator in print and radio, as well as an author. He has extensive experience in the capital markets, corporate governance, project acquisition and corporate finance. He is a named inventor on several of Lexaria's pending patents. Since 1988, Mr. Bunka has been the CEO of CAB Financial Services Ltd., a private holding company located in Kelowna, BC, Canada. He is a venture capitalist and corporate consultant.- Christopher Bunka自2006年以来一直担任董事会主席兼首席执行官，主要负责公司从较早的业务活动转向生物科学。Bunka先生是一位连续企业家，自1980年末以来一直在几家私营和上市公司工作。他作为印刷和广播电台的兼职商业评论员以及作家而闻名十多年。他在资本市场，公司治理，项目收购和公司融资方面拥有丰富的经验。他是该公司一些正在申请专利的发明家。自1988年以来，Bunka先生一直担任CAB Financial Services Ltd.的首席执行官，这是一家位于加拿大基洛纳的私人控股公司。他是一位风险投资家和企业顾问。
- Christopher Bunka,– Chairman, Chief Executive Officer and Director Mr. Bunka has been Chairman of the Board and CEO since 2006 and was primarily responsible for the corporate pivot from older business activities to bioscience. Mr. Bunka is a serial entrepreneur and has been involved in several private and public companies since the late 1980's. He was well known for more than a decade as a part-time business commentator in print and radio, as well as an author. He has extensive experience in the capital markets, corporate governance, project acquisition and corporate finance. He is a named inventor on several of Lexaria's pending patents. Since 1988, Mr. Bunka has been the CEO of CAB Financial Services Ltd., a private holding company located in Kelowna, BC, Canada. He is a venture capitalist and corporate consultant.
- John Docherty
John Docherty被任命为公司总裁，于2015年4月15日生效。在加入公司之前，Docherty先生是HELIX BIOPHARMACORP.的前总裁兼首席运营官。TSX:HBP，在那里他领导公司的植物和重组衍生的治疗性蛋白质候选产品的药物开发计划。Docherty先生是一位高级运营和管理执行官，在制药和生物制药领域拥有20多年的经验。他曾与大型跨国公司以及新兴的私营和上市初创企业合作。在Helix，Docherty先生还在投资者/利益相关者关系，资本筹集，资本市场发展，战略合作伙伴关系，监管机构互动和媒体关系领域发挥了重要作用，他还担任其董事会管理成员。在此之前，Docherty先生是Pharmaderm Laboratories Ltd.的总裁兼董事会成员，Pharmaderm Laboratories Ltd.是一家加拿大药物输送公司，开发了独特的微胶囊制剂技术，可用于一系列活性化合物。Docherty先生还曾在Astra Pharma Inc.，Nu-Pharm Inc.和Price Water House Coopers’；前全球制药行业咨询业务等公司任职。他是已发布专利和未决专利申请的指定发明人，并拥有理学硕士学位。药理学学士学位。多伦多大学毒理学博士学位。自2016年4月29日起担任公司董事。
John Docherty,was appointed President of Lexaria effective April 15, 2015. Prior to Lexaria Mr. Docherty was former President and Chief Operating Officer of Helix BioPharma Corp. (TSX: HBP), where he led the company's pharmaceutical development programs for its plant and recombinantly derived therapeutic protein product candidates.Mr. Docherty is a senior operations and management executive with over 20 years' experience in the pharmaceutical and biopharmaceutical sectors. He has worked with large multinational companies and emerging, private and publicly held start-ups. At Helix, Mr. Docherty was instrumental in the areas of investor/stakeholder relations, capital raising, capital markets development, strategic partnering, regulatory authority interactions and media relations. He also served as a management member of its board of directors. Previously, Mr. Docherty was President and a board member of PharmaDerm Laboratories Ltd., a Canadian drug delivery company that developed unique microencapsulation formulation technologies for Lexaria Bioscience Corp. e with a range of active compounds.Mr. Docherty also held positions with companies such as Astra Pharma Inc., Nu-Pharm Inc. and PricewaterhouseCoopers' former global pharmaceutical industry consulting practice. He is a named inventor on issued and pending patents and he has a M.Sc. in pharmacology and a B.Sc. in Toxicology from the University of Toronto. He has served as a director of Lexaria since April 29, 2016.- John Docherty被任命为公司总裁，于2015年4月15日生效。在加入公司之前，Docherty先生是HELIX BIOPHARMACORP.的前总裁兼首席运营官。TSX:HBP，在那里他领导公司的植物和重组衍生的治疗性蛋白质候选产品的药物开发计划。Docherty先生是一位高级运营和管理执行官，在制药和生物制药领域拥有20多年的经验。他曾与大型跨国公司以及新兴的私营和上市初创企业合作。在Helix，Docherty先生还在投资者/利益相关者关系，资本筹集，资本市场发展，战略合作伙伴关系，监管机构互动和媒体关系领域发挥了重要作用，他还担任其董事会管理成员。在此之前，Docherty先生是Pharmaderm Laboratories Ltd.的总裁兼董事会成员，Pharmaderm Laboratories Ltd.是一家加拿大药物输送公司，开发了独特的微胶囊制剂技术，可用于一系列活性化合物。Docherty先生还曾在Astra Pharma Inc.，Nu-Pharm Inc.和Price Water House Coopers’；前全球制药行业咨询业务等公司任职。他是已发布专利和未决专利申请的指定发明人，并拥有理学硕士学位。药理学学士学位。多伦多大学毒理学博士学位。自2016年4月29日起担任公司董事。
- John Docherty,was appointed President of Lexaria effective April 15, 2015. Prior to Lexaria Mr. Docherty was former President and Chief Operating Officer of Helix BioPharma Corp. (TSX: HBP), where he led the company's pharmaceutical development programs for its plant and recombinantly derived therapeutic protein product candidates.Mr. Docherty is a senior operations and management executive with over 20 years' experience in the pharmaceutical and biopharmaceutical sectors. He has worked with large multinational companies and emerging, private and publicly held start-ups. At Helix, Mr. Docherty was instrumental in the areas of investor/stakeholder relations, capital raising, capital markets development, strategic partnering, regulatory authority interactions and media relations. He also served as a management member of its board of directors. Previously, Mr. Docherty was President and a board member of PharmaDerm Laboratories Ltd., a Canadian drug delivery company that developed unique microencapsulation formulation technologies for Lexaria Bioscience Corp. e with a range of active compounds.Mr. Docherty also held positions with companies such as Astra Pharma Inc., Nu-Pharm Inc. and PricewaterhouseCoopers' former global pharmaceutical industry consulting practice. He is a named inventor on issued and pending patents and he has a M.Sc. in pharmacology and a B.Sc. in Toxicology from the University of Toronto. He has served as a director of Lexaria since April 29, 2016.